IBP (Indication Based Pricing)

Listado de revistas y artículos seleccionados

• American Journal of Public Health
• Annals of Internal Medicine
  • Why the United States Needs a National, Coordinated Biobanking System
  • Trends in Outpatient Care for Medicare Beneficiaries and Implications for Primary Care, 2000 to 2019
  • The Future of Medical Guidelines: Standardizing Clinical Care With the Humility of Uncertainty
• Annals of Oncology
  • I607P Trends in cancer imaging by indication, care setting, and hospital type during the COVID-19 pandemic and recovery
• Applied Health Economics and Health Policy
  • How to Cost the Implementation of Major System Change for Economic Evaluations: Case Study Using Reconfigurations of Specialist Cancer Surgery in Part of London, England 
  • Pricing and Reimbursement of Patent‑Protected Medicines: Challenges and Lessons from South‑Eastern Europe
  • Revisiting the Relationship Between Price Regulation and Pharmaceutical R&D Investment 
  • Translating Research to Policy: Setting Provider Payment Rates for Strategic Purchasing under India's National Publicly Financed Health Insurance Scheme 
  • Price Reduction of Anticancer Drugs from 2007 to 2019 in South Korea: The Impact of Pharmaceutical Cost-Containment Policies 
  • Systematic Review of Health State Utility Values Used in European Pharmacoeconomic Evaluations for Chronic Hepatitis C: Impact on Cost‑Effectiveness Results 
  • Multi-indication and Combination Pricing and Reimbursement of Pharmaceuticals: Opportunities for Improved Health Care through Faster Uptake of New Innovations
• Atención Primaria
  • Oferta de servicios de atención farmacéutica: clave para un nuevo modelo de servicios de salud
• British Medical Journal (BMJ)
  • Regulatory and clinical consequences of negative confirmatory trials of accelerated approval cancer drugs: retrospective observational study
  • Multivariate and network meta-analysis of multiple outcomes and multiple treatments: rationale, concepts, and examples 
• Canadian Medical Association Journal
• Cancer Discovery
• Circulation
• Clinical Pharmacology & Therapeutics
  • The “Coming of Age” of Real-World Evidence in Drug Development and Regulation
  • Real-World Evidence in EU Medicines Regulation: Enabling Use and Establishing Value
  • When Can We Trust Real-World Data To Evaluate New Medical Treatments? 
  • When Can We Rely on Real-World Evidence to Evaluate New Medical Treatments?
  • Evolving Acceptance and Use of RWE for Regulatory Decision Making on the Benefit/Risk Assessment of a Drug in Japan
  • Use of Real-World Evidence to Drive Drug Development Strategy and Inform Clinical Trial Design 
  • When Can Nonrandomized Studies Support Valid Inference Regarding Effectiveness or Safety of New Medical Treatments?
  • Regulator-Requested Non-Interventional Postauthorization Safety and Effectiveness Studies for Oncology Drugs: A Systematic Review
  • Emulating Control Arms for Cancer Clinical Trials Using External Cohorts Created From Electronic Health Record-Derived Real-World Data
• Cochrane Library
• Diabetes Cares
• EMBO Journal
• Epidemiology
  • A (Flexible) Synthetic Control Method for Count Data and Other Nonnegative Outcomes
• European Journal of Health Economics
  • Has the development of cancer biomarkers to guide treatment improved health outcomes? 
  • How relevant are social costs in economic evaluations? The case of Alzheimer’s disease 
• European Journal of Hospital Pharmacy. Science and Practice
  • Improving the aseptic transfer procedures in hospital pharmacies part C: evaluation and redesign of the transfer process
  • Budget impact analysis of two pharmaceutical management models in relation to the administration of intravenous anti-infective therapy in a Spanish nursing home - ProQuest
  • 1ISG-023 Pharmacoeconomic analysis of reference bevacizumab: opportunity for improved efficiency - ProQuest
• European Journal of Public Health
• Gaceta Sanitaria
  • Índice de valor social añadido: una propuesta para analizar la eficiencia hospitalaria
• Health Affairs
  • How Price Regulation Is Needed To Advance Market Competition - ProQuest
  • New Medicare Technology Add-On Payment Could Be Used As A Market Support Mechanism To Accelerate Antibiotic Innovation - ProQuest
  • Price Differences To Insurers For Infused Cancer Drugs In Hospital Outpatient Departments And Physician Offices - ProQuest
• Health Economics
  • Pricing vaccines and drugs in Europe: worth differentiating? 
• Health Economics Review
  • The cost-utility of early use of high-flow nasal cannula in bronchiolitis 
  • Using point-of-care diagnostic testing for improved antibiotic prescription: an economic model 
  • Arrangements with the NHS for providing healthcare services: do they improve financial performance of private for-profit hospitals in Spain? 
  • Can adaptive clinical trials help to solve the productivity crisis of the pharmaceutical industry? - a scenario analysis 
  • Micro-costing in health and medicine: a critical appraisal 
• Health Economics, Policy and Law
  • State strategies to address medicaid prescription spending: negotiated pricing vs price transparency 
  • Excessive pricing in the pharmaceutical industry: adding another string to the bow of EU competition law 
• Health Services Research 
  • The association of vertically integrated care with health care use and outcomes 
• International Journal of Technology Assessment in Health Care
• International Journal on Quality in Health Care
• Journal of American Medical Association (JAMA) / JAMA Oncology
  • The Oncologic Drugs Advisory Committee Votes of April 2021—Implications for the Fate of Accelerated Approval
• Joint Commission Journal on Quality Improvement
• Journal of Clinical Epidemiology
• Journal of Clinical Oncology
• Journal of Comparative Effectiveness Research
  • Medication review with follow-up for cardiovascular outcomes: a trial based cost–utility analysis 
• Journal of Epidemiology & Community Health
• Journal of General Internal Medicine
  • Estimating Discounts for Top Spending Drugs in Medicare Part D
• Journal of Health Economics
  • Hospital Pricing Following Integration with Physician Practices
  • Alternative payment models and physician treatment decisions: Evidence from lower back pain
  • The economics of medical procedure innovation
  • Does the framing of patient cost-sharing incentives matter? the effects of deductibles vs. no-claim refunds 
• Journal of Healthcare Quality Research
• Journal of Public Health Medicine
  • Effect Modifiers and Statistical Tests for Interaction in Randomized Trials 
  • The evaluation of diagnostic tests: evidence on technical and diagnostic accuracy, impact on patient outcome and cost-effectiveness is needed 
• The Lancet (UK)
• Lancet Oncology
• Medical Care
  • A Comparison of Home Health Utilization, Outcomes, and Cost Between Medicare Advantage and Traditional Medicare 
• Medical Care Research and Review
  • Does the Implementation of Reference Pricing Result in Reduced Utilization? Evidence From Inpatient and Outpatient Procedures  
  • The Price to Consumers of Generic Pharmaceuticals: Beyond the Headlines 
  • Incorporating Prescription Drug Utilization Information Into the Marketplace Risk Adjustment Model Improves Payment Accuracy and Reduces Adverse Selection Incentives 
• Medical Decision Making
• Medicina Clínica (Barcelona)
• Natura
• New England Journal of Medicine
• Pharmacoeconomics
  • The Challenges of Outcomes‑Based Contract Implementation for Medicines in Europe - ProQuest
  • Empirical Estimates of the Marginal Cost of Health Produced by a Healthcare System: Methodological Considerations from Country-Level Estimates - ProQuest
  • A Practical Guide to Modeling and Conducting a Cost‑Effectiveness Analysis of Companion Biomarker Tests for Targeted Therapies Using R: Tutorial Paper - ProQuest
  • Characterization of the Pharmaceutical Risk-Sharing Arrangement Process in Catalonia - ProQuest
  • Guidance for the Harmonisation and Improvement of Economic Evaluations of Personalised Medicine - ProQuest
• Plos Medicine
• Precision and Future Medicine
  • Widening role of multidisciplinary treatment for rectal cancer: toward diversity of cancer care
  • Pharmacogenetics-based personalized treatment in patients with inflammatory bowel disease: A review 
• Revista Española de Salud Pública
  • Análisis de la seguridad del paciente en el proceso de prescripción de medicamentos en investigación 
• Revista Española Economía de la Salud
  • Distribución farmacéutica: un compromiso con la salud del planeta (y su salud económica)
• Social Science & Medicine
  • Product patents and access to innovative medicines
  • Hospital response to a case-based payment scheme under regional global budget: The case of Guangzhou in China   
  • Microcredit as a public health initiative? Exploring mechanisms and pathways to health and wellbeing 
  • Willingness to pay for quality and length of life gains in end of life patients of different ages 
  • Healthcare policy by other means: Cancer clinical research as “oncopolicy” 
• The Office of Health Economics
  • Payment Models for Multi-Indication Therapies
  • A Case Study Analysis: Challenges in the NICE Evaluation of Multi-Indication Medicines for Rare and Ultra-Rare Diseases 
  • The Lower Drug Costs Now Act and Pharmaceutical Innovation 
  • Key Considerations for Early Access Schemes for Single-Administration (One-Time) Therapies 
  • Exploring the Financial Sustainability of Gene Therapies 
  • The Promise of Gene Therapies: Are we Ready? 
  • Why we need a new Outcomes-based Value Attribution Framework for Combination Regimens in Oncology 
  • Limitations of CBO’s Simulation Model of New Drug Development as a Tool for Policymakers 
  • It Takes Two to Tango: When do Conditional Reimbursement Risk-Sharing Schemes Work for Both Parties? 
  • Making Outcome-Based Payment a Reality in the NHS. Phase Two: Practical Considerations 
• Therapeutics and Clinical Risk Management
• Value in Health
  • Varying Willingness to Pay Based on Severity of Illness: Impact on Health Technology Assessment Outcomes of Inpatient and Outpatient Drug Therapies in The Netherlands 
  • A Perspective on Suitability of a Cost-Based Pricing Methodology for Repurposed Orphan Medicines: A Consideration of the Overall Value Proposition
  • Coverage and Pricing Recommendations of the French National Health Authority for Innovative Drugs: A Retrospective Analysis From 2014 to 2020 
  • Branded Price Variation in the United States Drug Market, 2010 to 2019 
  • Drug Prices and Value of Oncology Drugs in Italy 
  • Are Drugs Priced in Accordance With Value? A Comparison of Value-Based and Net Prices Using Institute for Clinical and Economic Review Report

​Extras: 

• National Institute for Health and Care Excellence (NICE, UK) 
  • NICE launches ambitious strategy to provide quicker access to new treatments and innovations
• Institute for Clinical and Economics Review (ICER, USA)
  • Strengthening the FDA’s Accelerated Approval Pathway